Onco Actu du 26 septembre 2016

	1. Biologie
New insights on how brain tumours spread and become resistant to therapy [Karolinska Institutet] The researchers examined the protein levels of SOX9 in malignant childhood brain tumours from more than 140 patients together with scientists in Germany.
	3.1.1 Tabac - e-cigs
Japan Tobacco to roll out e-cigarette next year [Reuters] Japan Tobacco, the world's third-largest tobacco company whose top brands include Winston, Mevius and Benson & Hedges, has invested heavily in expanding its production capacity for Ploom Tech tobacco capsules after it hit supply constraints in March following a test launch in the southern city of Fukuoka.
	4. Dépistage, diagnostic et pronostic
Chromosomal Instability Score May Predict Response to Cancer Treatment [NCI] The biomarker is a score based on the expression levels of a set of genes involved in partitioning chromosomes during cell division. This score, the researchers found, could identify tumors that would likely not respond to certain treatments and those that would be sensitive.
	4.1 Dép., diag. & prono. - Prostate
New Nuclear-Imaging Tests Show Promise in Locating Cancer [Wall Street Journal] Blue Earth Diagnostics Ltd., based in Oxford, England, developed the prostate imaging agent, called Axumin, based on a molecule originally developed by Mark Goodman, a professor of radiology and imaging sciences at Emory University’s School of Medicine in the mid-1990s.
	5.10 Traitements - Essais
Protecting the Patients and their Prostates from Physician Bias: Thoughts on the PROTECT Trial by Dr. Bishal Gyawali [ecancer News] I discovered a very sad thing in this debate, and that is the fact that doctors were camped into “PSA-lovers” and “PSA-haters” groups! I couldn’t believe my eyes when I read statements like these: “PSA-haters are gonna show the mortality graphs but..” and “PSA-lovers must be very happy that metastases rates were lower…."
	5.12 Immunothérapies
Beware the hype: Top scientists cautious about fighting cancer with immunotherapy [STAT] “Be critical,” said Dr. Philip Greenberg of the University of Washington, who’s also scientific co-founder of Juno Therapeutics, one of the companies leading the search for immune-based treatments for cancer. “Don’t believe everything you hear.”
Genomic alterations in IFN-γ pathway underlie resistance to anti-CTLA-4 (Yervoy) therapy [NIHilist's Immunology] For this study the authors compared 12 patients who did not respond to ipilimumab therapy (non-responders) and 4 patients who did respond to ipilimumab therapy (responders).
	5.3 Traitements - FDA, EMA,...
Thumbs Up/Thumbs Down: The FDA damaged itself badly with the Sarepta OK [EndPoints] Califf’s decision to bow to Janet Woodcock on Sarepta hurts the entire biotech industry.
	6.10 Politiques
Who's WHO? Six candidates named for next World Health Organisation chief [The Guardian] Ministers and academics from France, Ethiopia, Pakistan, Italy, Hungary and UK will vie to succeed Margaret Chan as director general in July 2017.
	6.10.1 Politiques (USA)
No Moonshot Funds In House & Senate FY17 Appropriations Bills [The Cancer Letter] Despite great bipartisan breast-beating in support of boosting the NCI and NIH budgets, Congress has not dedicated funding for the moonshot, a broad scientific and public health effort focused on improving clinical trials, data sharing, and streamlining regulatory processes for oncology products at FDA.
	6.11 Patients
Cancer patients sign up for trials of new drugs with too high hopes [The Telegraph] Research on more than 300 cancer patients asked about taking part in early-stage research found almost half believed their tumours would shrink, with hopes rising after they discussed the trials with their doctors. In fact, phase I clinical trials – which are the first experiments on humans following studies on laboratory animals, produce typical cancer response rates of between 4 per cent and 20 per cent.
	6.3 Associations/Fondations
Money isn't enough. Medical research needs a cultural revolution [The Guardian] If Zuckerberg and Chan want to get some bang for their buck, they’ll need to break down the structures that hold brilliant young scientists back.
Cure all diseases? The Chan Zuckerberg plan is brilliantly bold [The Guardian] “We have to be bold about the scale of the challenge we face in improving human health,” says Steve Caddick, professor of chemical biology at University College London and director of innovation at the Wellcome Trust, the world’s largest biomedical research charity.
	6.6 Publications
Meet the world’s top peer reviewer [STAT] Publons created the prizes “to honour the expert peer reviewers and editors who stand guard over research quality, and lead the charge for better, faster science.”
	6.7.2 Applis
ResearchKit update: Notes from the field on trial retention, Android integration, and more [MobiHealthNews] Though hard numbers were rare, most of the participants admitted that the next big challenge for ResearchKit would be to keep patients coming back long enough to derive the data the study needs. “When you move to mobile, the new challenge is retention and engagement,” Wilbanks said.